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Abstract. A 28-year-old man from East Mediterranean area admitted with abdominal pain, weight 
loss and diarrhea. Barium x-ray studies showed segmentation, dilatation of bowel loops, mucosal 
folds  thickening  and  delayed  intestinal  transit.  Histological  examination  of  biopsy  specimens 
revealed villous atrophy and plasmacytic infiltration limited to mucosa and submucosa
tomography showed multiple lymphadenopathy in the abdomen. Serum protein electropheresis and 
immunoelectropheresis indicated elevated IgA concentration. Bone marrow aspiration and biopsy 
revealed presence of lymphoplasmacytic infiltration.
lymph nodes showed positivity for CD45
symptoms,  abdominal  lymphadenopathy  and  bone  marrow  infiltration  disappeared  and  IgA 
concentration decreased to norma
Introduction. Alpha heavy chain disease (α
described by Seligmann in 1968.
1 It is also known as 
“Mediterranean”  lymphoma  or  immunoproliferative
small intestinal disease (IPSID). IPSID is evaluated as 
a form of mucosa-associated lymphoid tissue 
lymphoma.
2  In  WHO  classification  of  lymphoid  and 
hematopoietic tissue, α-HCD is listed in mature B cell 
neoplasm as a special form of heavy chain di
The  classical  clinical  findings  of  α
diarrhea, weight loss and abdominal pain. They may 
have  palpable  abdominal  masses  and  exhibiting 
clubbing.
4-6 The majority of the patients with α
have been reported in Mediterranean, Middle Eastern,
Africa and Far East. Common demographic properties 
; Open Journal System 
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old man from East Mediterranean area admitted with abdominal pain, weight 
ray studies showed segmentation, dilatation of bowel loops, mucosal 
folds  thickening  and  delayed  intestinal  transit.  Histological  examination  of  biopsy  specimens 
revealed villous atrophy and plasmacytic infiltration limited to mucosa and submucosa
tomography showed multiple lymphadenopathy in the abdomen. Serum protein electropheresis and 
immunoelectropheresis indicated elevated IgA concentration. Bone marrow aspiration and biopsy 
revealed presence of lymphoplasmacytic infiltration. Immunohistochemical analysis of the intestine, 
lymph nodes showed positivity for CD45, CD-79, CD-20. After tetracycline treatment the patient’s 
symptoms,  abdominal  lymphadenopathy  and  bone  marrow  infiltration  disappeared  and  IgA 
concentration decreased to normal levels.
Alpha heavy chain disease (α-HCD) was 
It is also known as 
“Mediterranean”  lymphoma  or  immunoproliferative
IPSID is evaluated as 
associated lymphoid tissue (MALT) 
In  WHO  classification  of  lymphoid  and 
is listed in mature B cell 
as a special form of heavy chain disease.
3
The  classical  clinical  findings  of  α-HCD  are 
diarrhea, weight loss and abdominal pain. They may 
have  palpable  abdominal  masses  and  exhibiting 
The majority of the patients with α-HCD 
have been reported in Mediterranean, Middle Eastern,
Africa and Far East. Common demographic properties 
of  α-HCD  are  lower  socioeconomic  status,  poor 
personal hygiene, predominance male sex and a peak 
age between the first and third decades.
relation with Campylobacter jejuni and development o
α-HCD.
9
It is characterized by a diffuse and intense plasma 
cell infiltrate in the lamina propria of the small bowel 
mucosa along  with  the  synthesis  of abnormal  alpha
heavy chains without light chains.
deficiencies  and  hypogammmaglob
common. The immunoglobulin A level is generally not 
increased. Bone marrow involvement of disease such 
as is very rare.
14 In the current report, we present a case 
of  α - HCD with  bone  marrow 
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old man from East Mediterranean area admitted with abdominal pain, weight 
ray studies showed segmentation, dilatation of bowel loops, mucosal 
folds  thickening  and  delayed  intestinal  transit.  Histological  examination  of  biopsy  specimens 
revealed villous atrophy and plasmacytic infiltration limited to mucosa and submucosa. Computed 
tomography showed multiple lymphadenopathy in the abdomen. Serum protein electropheresis and 
immunoelectropheresis indicated elevated IgA concentration. Bone marrow aspiration and biopsy 
ohistochemical analysis of the intestine, 
After tetracycline treatment the patient’s 
symptoms,  abdominal  lymphadenopathy  and  bone  marrow  infiltration  disappeared  and  IgA 
HCD  are  lower  socioeconomic  status,  poor 
personal hygiene, predominance male sex and a peak 
age between the first and third decades.
7,8 There is a 
relation with Campylobacter jejuni and development of 
It is characterized by a diffuse and intense plasma 
cell infiltrate in the lamina propria of the small bowel 
mucosa along  with  the  synthesis  of abnormal  alpha-
heavy chains without light chains.
10-13 Anemia, vitamin 
deficiencies  and  hypogammmaglobulinemia  is 
common. The immunoglobulin A level is generally not 
increased. Bone marrow involvement of disease such 
In the current report, we present a case 
marrow  involvement andMediterr J Hematol Infect Dis 2012; 4: Open Journal System
Table 1. Laboratory data of the patient on admission
       Values      Patient                     Normal 
Complete Blood 
Count
White blood cell  22.5x10
3/mm3          4-10x103/mm
3 
Neutrophile 9.5 x10
3/mm
3   1.8-7 x10
3/mm
3
Lymphocyte 12.4 x10
3/mm
3          0.9-4.4 x10
3/mm
3
Monocyte 0.5 x10
3/mm
3   0.16-8 x10
3/mm
3
       Red blood cell 426x10
3/mm
3   450-590 x10
3/mm
3
Hemoglobin 11.6 g/dL                 13.5-17.5 g/dL
Platelets 361 x10
3/mm
3   150-350 x10
3/mm3
Bichemistry
Blood glucose 95 g/dL                   75-115 g/dL
Total protein 5.2 g/dL                  5.5-8.0 g/dL
Albumin 2.0 g/dL                  3.5-5.5 g/dL
Serum iron 42 µg/dL                  50-150 µg/dL
Serum iron binding 464 µg/dL    250-370 µg/dL
Folic acid 2.7 ng/mL    3.1-17.5 ng/mL
Serological  tests
C-reactive protein 6.3 mg/L                  0.08-3.1 mg/L
IgA 1870 mg/dL    60-309 mg/dL
IgG 476 mg/dL                614-1295 mg/dL
IgM 20 mg/dL                  53-334 mg/dL
Urine
D-xylose test/5h 1.2 g                        >4.5 g
Stool
Culture negative                    negative
Smear ova  negative                    negative
Smear parasite negative                    negative
Bone marrow             lymphoplasmacytic no infiltration
infiltration 
   
complete clinical response to tetracycline treatment in 
a young male.
Case  Presentation.  A  28-year-old  man  from  East 
Mediterranean area admitted to hematology department 
with  complaints  of  abdominal  pain,  diarrhea  and 
weight loss of 25 kg in the last six months. On clinical 
examination, his blood pressure was 110/70 mmHg and 
pulse rate was 90 beats/min (regular). He was pale with 
cachectic appearance. He had clubbing of the fingers, 
edema  and  evidence  of  dehydration.  There  were  no 
palpable lymph nodes or splenomegaly. The patient’s 
hemoglobin  level  was  11.6  g/dl,  hematocrit  level 
35.7%,  red  blood  cell  count  4.44x10
6/mm
3,  platelet 
count 361x10
3/mm
3, mean corpuscular volume 80.4 fl 
mean  corpuscular  hemoglobin  concentration  32.4%, 
total  white blood  cells  count 
22.5x10
3/mm
3(lymphocyte  count  12.4x10
3/mm
3), 
neutrophil 9.5x10
3/mm
3. Lymphocytosis was observed 
in  the  peripheral  blood  smear.  Erythrocyte 
sedimentation rate was 90 mm/h. The multiple plasma 
biochemical abnormalities included albumin 2.0 g/dl, 
total  protein  5.2  g/dl,  low  plasma  potassium  2.9 
mmol/L,  serum  iron  was  42  µg/dl  and  iron  binding 
capacity  464  µg/dl  as  well  as  iron  saturation  9%. 
Serum folic acid level was low while cobalamin and 
zinc  levels  were  normal. Bacteriological,  virological 
and  parasitological  studies  of  stools  revealed  no 
evidence for specific agents. Chest x-ray was normal 
and abdominal x-ray showed air levels in non-dilated 
large  bowel.  Barium  x-ray  studies  showed 
segmentation, dilatation of bowel loops, mucosal folds 
thickening  and  delayed  intestinal  transit.  Endoscopic 
examination  showed  mild  duodenitis.  There  was  no 
abnormality  in  colonoscopic  examination.  Computed 
tomographic  (CT)  scans  of  the  abdominal  region 
showed  multiple  mesenterical  lymphadenopathy  and 
thickening  of  small  bowel.  Maximal  size  of  lymph 
nodes were 3 centimetres on CT scan. The samples of 
duodenal  biopsies  revealed  moderate  infiltration  by 
normal appearing plasma cells. Microscopic evaluation 
of the duodenal biopsy sample revealed no evidence of 
Helicobacter  pylori. The  serum  IgG,  IgA  gliadin 
antibodies  and  IgA  endomysial  antibodies  were 
negative.  The  examination  of  stool  and  duodenal 
aspiration  fluid  for  parasites  was  normal.  The 
immunological profile was normal except of elevated 
IgA (Table 1). The increased IgA was polyclonal and 
an abnormal precipitin line of IgA with no response to 
light chains was found on immunoelectropheresis. In 
order to determine the extent of disease and to obtain a 
diagnostic  sample laparoscopy  was  performed. 
Histological examination of the excised jejunal biopsy 
showed  subtotal  villous  atrophy  and  dense  lympho-
plasmacytic  infiltration  limited  to  mucosa  and 
submucosa  (Figure 1).  The  extensive  plasmacytic 
infiltaration  was  established  in  mesenteric  lymph 
nodes. CD 20 were found positive in the mesenteric 
lymph node (Figure 2). In the immunohistochemical 
analysis  of  the  intestinal  and  lymph  node  biopsy 
material,  LCA,  CD-79,  CD-20  and  IgA  were  found 
positive while kappa and lambda heavy chain, IgD and 
IgM  were  found  negative  (Figure 3).  Bone  marrow 
aspiration  and  biopsy  revealed  diffuse 
lymphoplasmacytic  infiltration  (Figure 4). 
Malabsorption  was  confirmed  by  abnormal  D-xylose 
absorption (urine excretion of D-xylose was 1.20 g/5 h; 
normal value >4.5 g/5 h). Patient was put on long term 
treatment with tetracycline regimen (500 mg PO, four 
time, every day). His symptoms and physical condition 
improved and diarrhea disappeared at the second week. 
The  patient  appeared  normal  with  the  exception  of 
clubbing, that was still present at the third month. The 
lymphocytosis resolved about three months. Follow-up 
CT of the abdomen showed no abnormality at the sixth 
month. Serum IgA concentration decreased to normal 
levels and bone marrow examination performed on the 
6
th month  revealed  normal  trilineal  hematopoiesis 
without  any  evidence  of  lymphoplasmacytic
infiltration. Tetracycline  treatment  continued  as  one 
year,  as  advised  in  the  literature.
4,6 Currently,  the 
patient has been disease-free, in the 8
th year after his 
treatment.Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
Figure 1. The biopsy sample of the jejunum illustrating complete effacement due to centrocyte like cells and plasma cells in the in muc
and submucosa  (HEx50 and 100)
Figure 2. CD 20 staining shows marked positivity of the lymphoid cells noted in the 
Discussion.  Alpha-heavy  chain  disease  is  frequently 
seen in Mediterranean countries and Middle East.
It  can  involve  stomach,  colon,  liver,  peritoneum, 
periaortic and cervical lymph nodes.
15 The involvement 
of  bone  marrow  and  increase  of  immunoglobulin  A 
level in α-HCD is very rare.
14 The histological findings 
of  α-HCD  have  been  classified  into  three  disti
stages:  Stages  A  includes  mature  plasmacytic  or 
lymphoplasmacytic  infiltration  of  mucosal  lamina 
: Open Journal System
       
The biopsy sample of the jejunum illustrating complete effacement due to centrocyte like cells and plasma cells in the in muc
CD 20 staining shows marked positivity of the lymphoid cells noted in the mesenteric lymph node
heavy  chain  disease  is  frequently 
and Middle East.
4,10,11
It  can  involve  stomach,  colon,  liver,  peritoneum, 
The involvement 
of  bone  marrow  and  increase  of  immunoglobulin  A 
The histological findings 
HCD  have  been  classified  into  three  distinct 
stages:  Stages  A  includes  mature  plasmacytic  or 
lymphoplasmacytic  infiltration  of  mucosal  lamina 
propria  and  mesenteric  lymph  nodes.  Stage  B  has 
nodular  mucosal  infiltrates  and  infiltrate  may  extend 
below  the  muscularis  mucosa.  The  plasma  cells 
frequently  are  atypical  and  some  immunoblasts  are 
seen. Stage C consist of lymphomatoid masses and a 
diffuse “immunoblastic” lymphoma with or without the 
benign  appearing  lymphoblastic  infiltration  seen  in 
stage A.
16
The biopsy sample of the jejunum illustrating complete effacement due to centrocyte like cells and plasma cells in the in mucosa 
mesenteric lymph node (CD20x100)
propria  and  mesenteric  lymph  nodes.  Stage  B  has 
nodular  mucosal  infiltrates  and  infiltrate  may  extend 
below  the  muscularis  mucosa.  The  plasma  cells 
tly  are  atypical  and  some  immunoblasts  are 
seen. Stage C consist of lymphomatoid masses and a 
diffuse “immunoblastic” lymphoma with or without the 
benign  appearing  lymphoblastic  infiltration  seen  in Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
Figure 3. CD 20 staining shows marked positivity of the lymphoid cells noted in the intestinal mucosa (CD20x100)
Figure  4. The  bone  marrow  aspirate  smear  shows  markedly 
increased  number  of  lymphoplasmacytic  (MGG  stain  Oil 
immersion X1000)
The presented case had some characteristics of α-
HCD  disease.  The  dense  infiltration  of 
lymphoplasmacytic in the mucosa and submucosa of 
jejunum and lymph nodes caused chronic diarrhea and 
abdominal  pain.  Immunohistochemical  staining  of 
intestine  revealed CD45  (LCA),  CD-79,  CD-20  and 
IgA positivity (Figure 1 and 2). D-xylose absorption 
test  in  patient  confirmed  the  absorption  disorder.  In 
addition, serum electrophoresis indicated the presence 
of  alpha  heavy  chain  without  accompanying  light 
chains. All these data is supportive of the α-HCD.
4,17,18 
Crohn’s  disease  and  Celiac  Sprue  was  thought  in 
differential  diagnosis.  Serologic  assays  and  clinical 
presentation  was  against  the  diagnosis  of  Celiac 
disease.  In  Crohn’s  disease,  microscopic  evaluation 
reveals neutrophilic infiltration and linear ulceration or 
fissures  that  were  not  present  in  this  patient.  No 
granulomatous  disease  was  noted  in  the  histological 
examination and parasite ova in stool were not seen. 
Our  patient  has  no  antiendomysial  antibody  and 
intraepithelial lymphocytosis. Therefore, we excluded 
Crohn’s  disease,  Celiac  sprue,  intestinal  tuberculosis 
and parasitosis. Our patient appeared to belong to stage 
A  lesion  because  of  only  lymphoplasmocytic 
infiltration in mucosa and submucosa with mesenteric 
nodes  without  regard  to  bone  marrow  involvement. 
According  to  our  knowledge;  there  is  no  consensus 
about stage of heavy chain disease with bone marrow 
involvement.  In  addition,  the  elevation  of 
immunoglobulin A level an other interesting feature of 
presented case.
The treatment modality depends on the extent and 
histological  stage  of  alpha-heavy  chain  disease. 
Because  of  the  frequent  presence  of  small  intestinal 
bacterial overgrowth and progression to malabsorbtion, 
the recommended treatment for stage A has been broad 
spectrum antibiotics with or without corticosteroids.
14-
19  The  average  complete  remission  rate  treated  with 
antibiotics is reported to be around 30-70% Treatment 
duration,  was  six  months,  minimally.
4 Some  authors 
suggest a 3 months additional antibiotic treatment, after Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
complete remission.
17
Our  patient  responded  to  tetracycline  at  second 
week of treatment and remained symptom free at the 
third month of tetracycline treatment. Serum IgA level 
decreased  to  normal  levels  and  bone  marrow 
infiltration  disappeared  at  sixth  month.  The 
lymphocytosis resolved about three months. Due to the 
clinical  presentations  and  the  clinical  responses 
observed in some patients treated with antibiotics, there 
has  been a significant consideration for an  unknown 
organism as the pathogenic factor for the development 
of alpha chain disease. Using 16S ribosomal sequence 
as  a  target,  a  recent  study  by  Lecuit  et  al.
9
demonstrated  Campylobacter  jejuni in  the  intestinal 
biopsy  from patients  with IPSID.  The  organism  was 
also  demonstrated  by  a  probe  hybridizing  to 
Campylobacter  jejuni.  Interestingly,  one  of  these 
patients had a clinical response to antibiotic treatment. 
We  believe  the  dramatic  response  to  tetracycline 
therapy  noted  in  our  patient  fits  to  the  proposed 
concept of an organism is primarily responsible for this 
disease. New clinical trials are likely to provide a better 
understanding of  the  etiology of  alpha  chain  disease 
and  develop  more  targeted  therapy  against 
Campylobacter jejuni. 
In the advanced alpha-heavy chain disease, in stage 
B  and  C,  recommended  treatment  consists  of 
antibiotics  and  different  chemotherapeutic  drug 
combinations (such as cylophosphamide, doxorubicine, 
vincristine,  bleomycine,  prednisolone,  nitrogen 
mustard,  procarbasine)  and/or  total  abdominal 
radiation.  Rambaund  and  Halphen
20 recommended 
first-line  antibiotics  for  early  stage  patients.  Patients 
without marked improvement after a 6-month course of 
antibiotic  or  complete  remission  within  12  months 
should  be  given doxorubicin  induced  chemotherapy. 
Up to 69% complete remission rate for stage B and C 
were reported.
11,21 In the literature, the information is 
very limited  in  alpha-heavy  chain  disease  with  bone 
marrow involvement. Bone marrow involvement is not 
effective  for  the  treatment  of  these  patients.
17,18  The 
bone marrow involvement in alpha-heavy chain disease 
is  very  rare.  The  bone  marrow  involvement  due  to 
alpha-heavy chain disease can be easily differentiated 
from  a  number  of  other  disorders  presenting  with 
malabsorbtion  as  there  is  a  typical  histopathological 
view. However, as noted in our patients, it is possible 
that  even  in  the  advanced  stage  disease  antibiotic 
therapy could be tried as the first line of treatment.
Conclusion. In summary, we present a rare systemic 
presentation  of  the  alpha-heavy  chain  disease  with 
bone  marrow  involvement.  This  case  illustrates  that 
remission may be possible with the administration of 
antibiotics such as tetracycline. Therefore, it is critical 
to  initiate a larger study with  alpha chain disease in 
order to determine precise etiology and response rate in 
this disorder.
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